Antiviral strategies for pandemic and seasonal influenza

Viruses

Volumn 2, Issue 8, 2010, Pages 1766-1781

  Hedlund, Maria ^a   Larson, Jeffrey L ^a   Fang, Fang ^a  

^a NexBio Inc   (United States)

Author keywords

Influenza virus; Neuraminidase inhibitors; RNA polymerase; Sialic acid

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; ANTIVIRUS AGENT; DAS 181; FAVIPIRAVIR; FLUDASE; LANINAMIVIR; LANINAMIVIR OCTANOATE; M2 ION CHANNEL BLOCKER; OSELTAMIVIR; PERAMIVIR; PLACEBO; RIBAVIRIN; RIMANTADINE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; ZANAMIVIR;

2009 H1N1 INFLUENZA; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANOREXIA; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ATAXIA; BEHAVIOR DISORDER; CONCENTRATION LOSS; CONFUSION; DELIRIUM; DEPRESSION; DISEASE DURATION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; HALLUCINATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VIRUS A; INSOMNIA; NAUSEA; NONHUMAN; PANDEMIC INFLUENZA; REVIEW; SEASONAL INFLUENZA; TREMOR; VIRUS STRAIN; VOMITING;

ORTHOMYXOVIRIDAE;

EID: 79952182888     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2081766     Document Type: Review

References (79)

1. Smith, N.M.; Bresee, J.S.; Shay, D.K.; Uyeki, T.M.; Cox, N.J.; Strikas, R.A. Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2006, 55, 1-42.
2. Weinstock, D.M.; Zuccotti, G. The evolution of influenza resistance and treatment. JAMA 2009, 301, 1066-1069.
3. Moscona, A. Oseltamivir resistance--disabling our influenza defenses. N. Engl. J. Med. 2005, 353, 2633-2636.
4. Zimmer, S.M.; Burke, D.S. Historical perspective--Emergence of influenza A (H1N1) viruses. N. Engl. J. Med. 2009, 361, 279-285.
5. Jefferson, T.; Demicheli, V.; Di, P.C.; Rivetti, D. Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst. Rev. 2006, CD001169, doi:10.1002/14651858.CD001169.pub3.
6. Suzuki, H.; Saito, R.; Masuda, H.; Oshitani, H.; Sato, M.; Sato, I. Emergence of amantadine resistant influenza A viruses: epidemiological study. J. Infect. Chemother. 2003, 9, 195-200.
7. Shinde, V.; Bridges, C.B.; Uyeki, T.M.; Shu, B.; Balish, A.; Xu, X.; Lindstrom, S.; Gubareva, L.V.; Deyde, V.; Garten, R.J.; Harris, M.; Gerber, S.; Vagoski, S.; Smith, F.; Pascoe, N.; Martin, K.; Dufficy, D.; Ritger, K.; Conover, C.; Quinlisk, P.; Klimov, A.; Bresee, J.S.; Finelli, L. Triple- Reassortant Swine Influenza A (H1) in Humans in the United States, 2005-2009. N. Engl. J. Med. 2009, 360, 2616-2625.
8. Dawood, F.S.; Jain, S.; Finelli, L.; Shaw, M.W.; Lindstrom, S.; Garten, R.J.; Gubareva, L.V.; Xu, X.; Bridges, C.B.; Uyeki, T.M. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 2009, 360, 2605-2615.
9. Rungrotmongkol, T.; Intharathep, P.; Malaisree, M.; Nunthaboot, N.; Kaiyawet, N.; Sompornpisut, P.; Payungporn, S.; Poovorawan, Y.; Hannongbua, S. Susceptibility of antiviral drugs against 2009 influenza A (H1N1) virus. Biochem. Biophys. Res. Commun. 2009, 385, 390-394.
10. Glaxo SmithKline Inc. Relenza (Zanamivir) Inhalation Powder, 2010. Available online: http://us.gsk.com/products/assets/us_relenza.pdf (accessed on 18 August 2010).
11. Roche Laboratories Inc. Tamiflu (Oseltamivir Phosphate) Capsules and for Oral Suspension, 2008. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021087s047,%20021246s033lbl.pdf (accessed on 18 August 2010).
12. Cooper, N.J.; Sutton, A.J.; Abrams, K.R.; Wailoo, A.; Turner, D.; Nicholson, K.G. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ 2003, 326, 1235-1242.
13. McGeer, A.; Green, K.A.; Plevneshi, A.; Shigayeva, A.; Siddiqi, N.; Raboud, J.; Low, D.E. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin. Infect. Dis. 2007, 45, 1568-1575.
14. Mishin, V.P.; Hayden, F.G.; Gubareva, L.V. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother. 2005, 49, 4515-4520.
15. Dharan, N.J.; Gubareva, L.V.; Meyer, J.J.; Okomo-Adhiambo, M.; McClinton, R.C.; Marshall, S.A.; St, G.K.; Epperson, S.; Brammer, L.; Klimov, A.I.; Bresee, J.S.; Fry, A.M. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301, 1034-1041.
16. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb. Mortal. Wkly. Rep. 2009, 58, 969-972.
17. Leung, T.W.; Tai, A.L.; Cheng, P.K.; Kong, M.S.; Lim, W. Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J. Clin. Virol. 2009, 46, 298-299.
18. WHO: Oseltamivir Resistance in Immuno compromised Hospital Patients. WHO. Available online: http://www.who.int/csr/disease/swineflu/notes/briefing_20091202/en/index.html (accessed on 13 August 2010).
19. WHO: Viruses Resistant to Oseltamivir (Tamiflu) Identified. WHO. Available online: http://www.who.int/csr/disease/swineflu/notes/h1n1_antiviral_resistance_20090708/en/index.html (accessed on 13 August 2010).
20. CDC: Seasonal Influenza: 2008-2009 Influenza Season Week 39. CDC. Available online: http://www.cdc.gov/flu/weekly/weeklyarchives2008-2009/weekly39.htm (accessed on 13 August 2010).
21. Wetherall, N.T.; Trivedi, T.; Zeller, J.; Hodges-Savola, C.; McKimm-Breschkin, J.L.; Zambon, M.; Hayden, F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 2003, 41, 742-750.
22. Triana-Baltzer, G.B.; Gubareva, L.V.; Klimov, A.I.; Wurtman, D.F.; Moss, R.B.; Hedlund, M.; Larson, J.L.; Belshe, R.B.; Fang, F. Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein. PLoS ONE 2009, 4, e7838.
23. Lackenby, A.; Thompson, C.I.; Democratis, J. The potential impact of neuraminidase inhibitor resistant influenza. Curr. Opin. Infect. Dis. 2008, 21, 626-638.
24. Gubareva, L.V.; Matrosovich, M.N.; Brenner, M.K.; Bethell, R.C.; Webster, R.G. Evidence for zanamivir resistance in an immuno compromised child infected with influenza B virus. J. Infect. Dis. 1998, 178, 1257-1262.
25. Beigel, J.; Bray, M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res. 2008, 78, 91-102.
26. Boltz, D.A.; Aldridge, J.R., Jr.; Webster, R.G.; Govorkova, E.A. Drugs in development for influenza. Drugs 2010, 70, 1349-1362.
27. De, C.E. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 2006, 5, 1015-1025.
28. Hsieh, H.P.; Hsu, J.T. Strategies of development of antiviral agents directed against influenza virus replication. Curr. Pharm Des. 2007, 13, 3531-3542.
29. Cass, L.M.; Efthymiopoulos, C.; Bye, A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin. Pharmacokinet. 1999, 36 (Suppl. 1), 1-11.
30. Calfee, D.P.; Peng, A.W.; Cass, L.M.; Lobo, M.; Hayden, F.G. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob. Agents Chemother. 1999, 43, 1616-1620.
31. Stittelaar, K.J.; Tisdale, M.; van, A.G.; van Lavieren, R.F.; Pistoor, F.; Simon, J.; Osterhaus, A.D. Evaluation of intravenous zanamivir against experimental influenza A (H5N1) virus infection in cynomolgus macaques. Antiviral Res. 2008, 80, 225-228.
32. Higgs, E.S.; Hayden, F.G.; Chotpitayasunondh, T.; Whitworth, J.; Farrar, J. The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. Antiviral Res. 2008, 78, 64-68.
33. Gubareva, L.V.; Webster, R.G.; Hayden, F.G. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob. Agents Chemother. 2001, 45, 3403-3408.
34. Bantia, S.; Arnold, C.S.; Parker, C.D.; Upshaw, R.; Chand, P. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res. 2006, 69, 39-45.
35. Barroso, L.; Treanor, J.; Gubareva, L.; Hayden, F.G. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir. Ther. 2005, 10, 901-910.
36. Kilpatrick J.M.; Harman, L.A.; Collis, P.J.; Aitee, G.; Mead, E.; Alexander, W.J. Pharmacokinetics and safety of peramivir by intramuscular administration. In Program and abstracts of the Options for the Control of Influenza Conference VI Conference. In Proceedings of the London International Society for Influenza and Other Respiratory Virus Diseases, Toronto, Canada, June 17-23 2007; Abstract Number P916.
37. BioCryst Pharmaceuticals I.: BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results. BioCryst Pharmaceuticals, Inc. May 8, 2009. Available online: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=382718 (accessed on 12 August 2010).
38. BioCryst Pharmaceuticals I.: BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza. BioCryst Pharmaceuticals, Inc. September 19, 2007. Available online: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=264815 (accessed on 12 August 2010).
39. BioCryst Pharmaceuticals I.: Data From Phase 2 Study of Peramivir in Patients Hospitalized With Influenza Presented at the XI International Symposium on Respiratory Viral Infections. BioCryst Pharmaceuticals, Inc. February 23, 2009. Available online: http://investor.shareholder.com/biocryst/releasedetail.cfm?ReleaseID=366984 (accessed on 12 August 2010).
40. Hurt, A.C.; Ernest, J.; Deng, Y.M.; Iannello, P.; Besselaar, T.G.; Birch, C.; Buchy, P.; Chittaganpitch, M.; Chiu, S.C.; Dwyer, D.; Guigon, A.; Harrower, B.; Kei, I.P.; Kok, T.; Lin, C.; McPhie, K.; Mohd, A.; Olveda, R.; Panayotou, T.; Rawlinson, W.; Scott, L.; Smith, D.; D'Souza, H.; Komadina, N.; Shaw, R.; Kelso, A.; Barr, I.G. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res. 2009, 83, 90-93.
41. Birnkrant, D.; Cox, E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N. Engl. J. Med. 2009, 361, 2204-2207.
42. Yamashita, M.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Nasu, H.; Kubo, S. CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob. Agents Chemother. 2009, 53, 3756-3764.
43. Biota: LANI Phase III Clinical Trials in Asia Prove Successful. Biota Press Release. August 10, 2009. Available online: http://www.biota.com.au/uploaded/154/1021542_25laniphaseiiiclinicaltri.pdf (accessed on 12 August 2010).
44. Furuta, Y.; Takahashi, K.; Kuno-Maekawa, M.; Sangawa, H.; Uehara, S.; Kozaki, K.; Nomura, N.; Egawa, H.; Shiraki, K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 2005, 49, 981-986.
45. Smee, D.F.; Hurst, B.L.; Egawa, H.; Takahashi, K.; Kadota, T.; Furuta, Y. Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J. Antimicrob. Chemother. 2009, 64, 741-746.
46. Furuta, Y.; Takahashi, K.; Shiraki, K.; Sakamoto, K.; Smee, D.F.; Barnard, D.L.; Gowen, B.B.; Julander, J.G.; Morrey, J.D. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009, 82, 95-102.
47. Kiso, M.; Takahashi, K.; Sakai-Tagawa, Y.; Shinya, K.; Sakabe, S.; Le, Q.M.; Ozawa, M.; Furuta, Y.; Kawaoka, Y. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 882-887.
48. Itoh, Y.; Shinya, K.; Kiso, M.; Watanabe, T.; Sakoda, Y.; Hatta, M.; Muramoto, Y.; Tamura, D.; Sakai-Tagawa, Y.; Noda, T.; Sakabe, S.; Imai, M.; Hatta, Y.; Watanabe, S.; Li, C.; Yamada, S.; Fujii, K.; Murakami, S.; Imai, H.; Kakugawa, S.; Ito, M.; Takano, R.; Iwatsuki-Horimoto, K.; Shimojima, M.; Horimoto, T.; Goto, H.; Takahashi, K.; Makino, A.; Ishigaki, H.; Nakayama, M.; Okamatsu, M.; Takahashi, K.; Warshauer, D.; Shult, P.A.; Saito, R.; Suzuki, H.; Furuta, Y.; Yamashita, M.; Mitamura, K.; Nakano, K.; Nakamura, M.; Brockman-Schneider, R.; Mitamura, H.; Yamazaki, M.; Sugaya, N.; Suresh, M.; Ozawa, M.; Neumann, G.; Gern, J.; Kida, H.; Ogasawara, K.; Kawaoka, Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009, 460, 1021-1025.
49. Gowen, B.B.; Smee, D.F.; Wong, M.H.; Hall, J.O.; Jung, K.H.; Bailey, K.W.; Stevens, J.R.; Furuta, Y.; Morrey, J.D. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS ONE 2008, 3, e3725.
50. Morrey, J.D.; Taro, B.S.; Siddharthan, V.; Wang, H.; Smee, D.F.; Christensen, A.J.; Furuta, Y. Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents. Antiviral Res. 2008, 80, 377-379.
51. Julander, J.G.; Shafer, K.; Smee, D.F.; Morrey, J.D.; Furuta, Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob. Agents Chemother. 2009, 53, 202-209.
52. Malakhov, M.P.; Aschenbrenner, L.M.; Smee, D.F.; Wandersee, M.K.; Sidwell, R.W.; Gubareva, L.V.; Mishin, V.P.; Hayden, F.G.; Kim, D. H.; Ing, A.; Campbell, E.R.; Yu, M.; Fang, F. Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob. Agents Chemother. 2006, 50, 1470-1479.
53. Ah-Tye, C.; Schwartz, S.; Huberman, K.; Carlin, E.; Moscona, A. Virus-receptor interactions of human parainfluenza viruses types 1, 2 and 3. Microb. Pathog. 1999, 27, 329-336.
54. Belser, J.A.; Lu, X.; Szretter, K.J.; Jin, X.; Aschenbrenner, L.M.; Lee, A.; Hawley, S.; Kim, d.H.; Malakhov, M.P.; Yu, M.; Fang, F.; Katz, J.M. DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection. J. Infect. Dis. 2007, 196, 1493-1499.
55. Nicholls, J.M.; Aschenbrenner, L.M.; Paulson, J.C.; Campbell, E.R.; Malakhov, M.P.; Wurtman, D.F.; Yu, M.; Fang, F. Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza. J. Antimicrob. Chemother. 2008, 62, 426-428.
56. Triana-Baltzer, G.B.; Babizki, M.; Chan, M.C.; Wong, A.C.; Aschenbrenner, L.M.; Campbell, E.R.; Li, Q.X.; Chan, R.W.; Peiris, J.S.; Nicholls, J.M.; Fang, F. DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis. J. Antimicrob. Chemother. 2010, 65, 275-284.
57. Chan, R.W.; Chan, M.C.; Wong, A.C.; Karamanska, R.; Dell, A.; Haslam, S.M.; Sihoe, A.D.; Chui, W.H.; Triana-Baltzer, G.; Li, Q.; Peiris, J.S.; Fang, F.; Nicholls, J.M. DAS181 inhibits H5N1 influenza virus infection of human lung tissues. Antimicrob. Agents Chemother. 2009, 53, 3935-3941.
58. Triana-Baltzer, G.B.; Gubareva, L.V.; Nicholls, J.M.; Pearce, M.B.; Mishin, V.P.; Belser, J.A.; Chen, L.M.; Chan, R.W.; Chan, M.C.; Hedlund, M.; Larson, J.L.; Moss, R.B.; Katz, J.M.; Tumpey, T.M.; Fang, F. Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein. PLoS ONE 2009, 4, e7788.
59. Triana-Baltzer, G.B.; Gubareva, L.; Nicholls, J.M.; Pearce, M.B.; Mishin, V.P.; Belser, J.A.; Chen, L.M.; Chan, R.W.Y.; Chan, M.C.W.; Hedlund, M.; Moss, R.B.; Katz, J.M.; Tumpey, T.M.; Fang, F. Novel Swine-Origin A(H1N1) Influenza Viruses are Potently Inhibited by DAS181, a Sialidase Fusion Protein. PLoS ONE 2009, 4, e7788.
60. Bantia, S.; Ghate, A.A.; Ananth, S.L.; Babu, Y.S.; Air, G.M.; Walsh, G.M. Generation and characterization of a mutant of influenza A virus selected with the neuraminidase inhibitor BCX- 140. Antimicrob. Agents Chemother. 1998, 42, 801-807.
61. Barnett, J.M.; Cadman, A.; Burrell, F.M.; Madar, S.H.; Lewis, A.P.; Tisdale, M.; Bethell, R. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 1999, 265, 286-295.
62. Baum, E.Z.; Wagaman, P.C.; Ly, L.; Turchi, I.; Le, J.; Bucher, D.; Bush, K. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res. 2003, 59, 13-22.
63. Gubareva, L.V.; Bethell, R.; Hart, G.J.; Murti, K.G.; Penn, C.R.; Webster, R.G. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J. Virol. 1996, 70, 1818-1827.
64. Gubareva, L.V.; Robinson, M.J.; Bethell, R.C.; Webster, R.G. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J. Virol. 1997, 71, 3385-3390.
65. McKimm-Breschkin, J.L.; McDonald, M.; Blick, T.J.; Colman, P.M. Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4- guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 1996, 225, 240-242.
66. McKimm-Breschkin, J.L.; Blick, T.J.; Sahasrabudhe, A.; Tiong, T.; Marshall, D.; Hart, G.J.; Bethell, R.C.; Penn, C.R. Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en. Antimicrob. Agents Chemother. 1996, 40, 40-46.
67. McKimm-Breschkin, J.L.; Sahasrabudhe, A.; Blick, T.J.; McDonald, M.; Colman, P.M.; Hart, G.J.; Bethell, R.C.; Varghese, J.N. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J. Virol. 1998, 72, 2456-2462.
68. McKimm-Breschkin, J.L. Resistance of influenza viruses to neuraminidase inhibitors--a review. Antiviral Res. 2000, 47, 1-17.
69. Molla, A.; Kati, W.; Carrick, R.; Steffy, K.; Shi, Y.; Montgomery, D.; Gusick, N.; Stoll, V.S.; Stewart, K.D.; Ng, T.I.; Maring, C.; Kempf, D.J.; Kohlbrenner, W. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675. J. Virol. 2002, 76, 5380-5386.
70. Smee, D.F.; Sidwell, R.W.; Morrison, A.C.; Bailey, K.W.; Baum, E.Z.; Ly, L.; Wagaman, P.C. Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. Antiviral Res. 2001, 52, 251-259.
71. Gubareva, L.V.; Bethell, R.; Hart, G.J.; Murti, K.G.; Penn, C.R.; Webster, R.G. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino- Neu5Ac2en. J. Virol. 1996, 70, 1818-1827.
72. Hedlund, M.; Aschenbrenner, L.M.; Jensen, K.; Larson, J.L.; Fang, F. Sialidase-based antiinfluenza virus therapy protects against secondary pneumococcal infection. J. Infect. Dis. 2010, 201, 1007-1015.
73. Wurtman, D. The Evolving Role of Antivirals. Presented at the Influenza Congress USA 2009, Washington, DC, USA, November 18-20, 2009.
74. Moss, R.B.; Davey, R.T.; Steigbigel, R.T.; Fang, F. Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. J. Antimicrob. Chemother. 2010, 65, 1086-1093.
75. Hayden, F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 2009, 48 (Suppl. 1), S3-S13.
76. Ilyushina, N.A.; Bovin, N.V.; Webster, R.G.; Govorkova, E.A. Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res. 2006, 70, 121-131.
77. Ison, M.G.; Gnann, J.W., Jr.; Nagy-Agren, S.; Treannor, J.; Paya, C.; Steigbigel, R.; Elliott, M.; Weiss, H.L.; Hayden, F.G. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir. Ther. 2003, 8, 183-190.
78. Ilyushina, N.A.; Hay, A.; Yilmaz, N.; Boon, A.C.; Webster, R.G.; Govorkova, E.A. Oseltamivirribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob. Agents Chemother. 2008, 52, 3889-3897.
79. Smee, D.F.; Hurst, B.L.; Wong, M.H.; Bailey, K.W.; Tarbet, E.B.; Morrey, J.D.; Furuta, Y. Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob. Agents Chemother. 2010, 54, 126-133.